

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptasjl1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	3	MAR 16	CASREACT coverage extended
NEWS	4	MAR 20	MARPAT now updated daily
NEWS	5	MAR 22	LWPI reloaded
NEWS	6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	10	APR 30	CA/CAPplus enhanced with 1870-1889 U.S. patent records
NEWS	11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	12	MAY 01	New CAS web site launched
NEWS	13	MAY 08	CA/CAPplus Indian patent publication number format defined
NEWS	14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	17	MAY 21	CA/CAPplus enhanced with additional kind codes for German patents
NEWS	18	MAY 22	CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS	19	JUN 27	CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS	20	JUN 29	STN Viewer now available
NEWS	21	JUN 29	STN Express, Version 8.2, now available
NEWS	22	JUL 02	LEMBASE coverage updated
NEWS	23	JUL 02	LMEDLINE coverage updated
NEWS	24	JUL 02	SCISEARCH enhanced with complete author names
NEWS	25	JUL 02	CHEMCATS accession numbers revised
NEWS	26	JUL 02	CA/CAPplus enhanced with utility model patents from China

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:49:14 ON 10 JUL 2007

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:49:25 ON 10 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUL 2007 HIGHEST RN 941818-42-4

DICTIONARY FILE UPDATES: 9 JUL 2007 HIGHEST RN 941818-42-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10551933-A.str

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10551933-B.str

L2 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10551933-C.str

L3 STRUCTURE UPLOADED

=> s l1 sss full

FULL SEARCH INITIATED 09:50:19 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 45490 TO ITERATE

100.0% PROCESSED 45490 ITERATIONS

284 ANSWERS

SEARCH TIME: 00.00.01

L4 284 SEA SSS FUL L1

=> s l2 sss full

FULL SEARCH INITIATED 09:50:26 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 45490 TO ITERATE

100.0% PROCESSED 45490 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

L5 2 SEA SSS FUL L2

=> s l3 sss full

FULL SEARCH INITIATED 09:50:32 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 686078 TO ITERATE

100.0% PROCESSED 686078 ITERATIONS  
SEARCH TIME: 00.00.04

5 ANSWERS

L6 5 SEA SSS FUL L3


=> s l4 or l5 or l6

L7 291 L4 OR L5 OR L6

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1


G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d l2

L2 HAS NO ANSWERS

L2 STR




G1

G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d 13  
L3 HAS NO ANSWERS  
L3 STR



G1  
G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> fil caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
516.30	516.51

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 09:51:15 ON 10 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jul 2007 VOL 147 ISS 3  
FILE LAST UPDATED: 9 Jul 2007 (20070709/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 09:49:14 ON 10 JUL 2007)

FILE 'REGISTRY' ENTERED AT 09:49:25 ON 10 JUL 2007

L1 STRUCTURE UPLOADED  
L2 STRUCTURE UPLOADED  
L3 STRUCTURE UPLOADED

L4 284 S L1 SSS FULL  
L5 2 S L2 SSS FULL  
L6 5 S L3 SSS FULL  
L7 291 S L4 OR L5 OR L6


FILE 'CAPLUS' ENTERED AT 09:51:15 ON 10 JUL 2007

=> s l7

L8 9 L7


=> d l8 tot bib abs hitstr

AN 2005:461153 CAPLUS  
 DN 143:125827  
 TI Novel ketal ligands for the glucocorticoid receptor: in vitro and in vivo activity  
 AU Smith, Cameron J.; Ali, Amjad; Balkovec, James M.; Graham, Donald W.; Hammond, Milton L.; Patel, Gool F.; Rouen, Gregory P.; Smith, Scott K.; Tata, James R.; Einstein, Monica; Ge, Lan; Harris, Georgianna S.; Kelly, Theresa M.; Mazur, Paul; Thompson, Chris M.; Wang, Chuanlin F.; Williamson, Joanne M.; Miller, Douglas K.; Pandit, Shilpa; Santoro, Joseph C.; Sitlani, Ayesha; Yamin, Ting-ting D.; O'Neill, Edward A.; Zaller, Dennis M.; Carballo-Jane, Ester; Forrest, Michael J.; Luell, Silvi  
 CS Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(11), 2926-2931  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier B.V.  
 DT Journal  
 LA English  
 OS CASREACT 143:125827  
 GI




AB A novel series of selective ligands for the human glucocorticoid receptor is described. Structure-activity studies focused on variation of B-ring size, ketal ring size, and ketal substitution. These analogs were found to be potent and selective ligands for GR and have partial agonist profiles in functional assays for transactivation (TAT, GS) and transrepression (IL-6). Of these compds., three were evaluated further in a mouse LPS-induced TNF- $\alpha$  secretion model. Compound (I) had an ED50 of 14.1 mg/kg compared with 0.5 mg/kg for prednisolone in the same assay.  
 IT 786708-06-3  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)  
 (novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)  
 RN 786708-06-3 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 786708-45-0P  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)  
 RN 786708-45-0 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4',5'-diethyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, stereoisomer (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 786708-33-6  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)  
 RN 786708-33-6 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6'-trimethyl-, (4'S,4aS,6'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 614762-99-1P 786707-55-9P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)  
 RN 614762-99-1 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-55-9 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 786707-70-8  
 RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)  
 (novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)  
 RN 786707-70-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 786707-65-1P 786707-67-3P 786707-68-4P

858371-49-0P 858371-51-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(novel ketal ligands for glucocorticoid receptor and in vitro and in vivo activity)

RN 786707-65-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-67-3 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-dipropyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN	858371-49-0	CAPLUS
CN	Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)- 1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-di-2-propenyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)	

The chemical structure consists of a 4-fluorophenyl group attached to the nitrogen of a benzimidazole system. The benzimidazole is fused to a cyclohexane ring, which has a methyl group (Me) attached to one of its carbons. This cyclohexane ring is further connected to a bicyclic acetal system. The acetal system features two oxygen atoms bridging two carbons, with vinyl groups (H<sub>2</sub>C=CH-) and 'R' groups attached to the carbons of the acetal ring.

RN	858371-51-4	CAPLUS
CN	Spiro[cyclopent[f]indazole-5(1H), 2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4',5'-di-2-propenyl-, (4'R,4aS,5'R) - (9CI) (CA INDEX NAME)	

Absolute stereochemistry.



IT 786707-63-9 786708-10-9 786708-11-0  
 786708-14-3 786708-15-4 786708-16-5  
 786708-17-6 786708-18-7 786708-19-8  
 786708-20-1 786708-21-2 786708-34-7  
 786708-36-9 787619-93-6 787620-00-2  
 787620-02-4 787620-09-1 787620-10-4  
 858371-54-7 858371-55-8 858371-57-0


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)

(novel ketal ligands for glucocorticoid receptor and in vitro and in  
 vivo activity)

RN 786707-63-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-, (4'R,4aS,5'R)- (9CI) (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 786708-10-9 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4a-methyl-4',5'-diphenyl-, (4'R,4aS,5'R)- (9CI) (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 786708-11-0 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',5'-bis(methoxymethyl)-4a-methyl-, (4'R,4aS,5'R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-14-3 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4'S,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-15-4 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'S,4'S,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-16-5 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-17-6 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-18-7 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry:



RN 786708-19-8 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-20-1 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-21-2 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'S,4'S,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-34-7 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a,5',5'-trimethyl-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-36-9 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4',4a,6'-tetramethyl-, (2'S,4aS,6'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787619-93-6 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-diphenyl-, (4'R,4aS,5'R)-(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 787620-00-2 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4',4a,6'-trimethyl-, (4'R,4aS,6'R)- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 787620-02-4 CAPLUS


CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




RN 787620-09-1 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4',4a,6'-trimethyl-, (4'R,4aS,6'R)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 787620-10-4 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4',4a,6'-trimethyl-, (4'R,4aS,6'S)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 858371-54-7 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4',4a-dimethyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 858371-55-8 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4',4a-dimethyl-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 858371-57-0 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4',4',4a,6',6'-pentamethyl-, (4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 786708-00-7P 786708-30-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (novel ketal ligands for glucocorticoid receptor and in vitro and in  
 vivo activity)

RN 786708-00-7 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-  
 1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-30-3 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H), 2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:927012 CAPLUS

DN 141:395547

TI Preparation of selective spirocyclic glucocorticoid receptor modulators  
IN Ali, Amjad; Balkovec, James M.; Beresis, Richard; Colletti, Steven L.;  
Graham, Donald W.; Patel, Gool F.; Smith, Cameron J.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 201 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004093805	A2	20041104	WO 2004-US12102	20040419
	WO 2004093805	A3	20051208		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
 TD, TG

AU 2004232301	A1	20041104	AU 2004-232301	20040419
CA 2522946	A1	20041104	CA 2004-2522946	20040419
EP 1617806	A2	20060125	EP 2004-760029	20040419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1809347	A	20060726	CN 2004-80017051	20040419
JP 2006524251	T	20061026	JP 2006-513140	20040419
US 2006217563	A1	20060928	US 2005-551933	20051004
PRAI US 2003-464784P	P	20030423		
WO 2004-US12102	W	20040419		
OS MARPAT 141:395547				
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title compds. I [Ring A = carbocyclyl or heterocyclyl; m = 0-3; n = 0-2; R1 = (un)substituted-alkyl, -alkenyl, -alkynyl, -cycloalkyl, etc.; R2 and R3 independently = H, halo, alkyl, aryl, etc.; R4 = OH, CO2H, (un)substituted-alkyl, -Ph, etc.] , as well as their pharmaceutically acceptable salts or hydrates thereof, are prepared and disclosed as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Thus, e.g., II was prepared via spirocyclization of III (preparation given) with Et  $\alpha$ -bromomethyl acrylate. In human glucocorticoid receptor assays, I demonstrated a range of GR affinity with IC50 values between 10  $\mu$ M and 1 nM. Pharmaceutical compns. and methods of use are also included.

IT 786706-22-7P 786706-34-1P 786706-35-2P  
 786706-42-1P 786706-43-2P 786706-45-4P  
 786706-49-8P 786706-50-1P 786706-56-7P  
 786706-62-5P 786707-01-5P 786707-07-1P  
 786707-08-2P 786707-10-6P 786707-14-0P  
 786707-16-2P 786707-19-5P 786707-23-1P  
 786707-24-2P 786707-26-4P 786707-28-6P  
 786707-52-6P 786707-53-7P 786707-54-8P  
 786707-55-9P 786707-56-0P 786707-57-1P  
 786707-62-8P 786708-06-3P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of pyrazoles bearing annulated spirocyclic hydronaphthalene derivs. as glucocorticoid receptor modulators)

RN 786706-22-7 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-(3'H)-furan], 1-(4-fluorophenyl)-  
 1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4'-methylene-, (2'R,4aS)- (9CI)  
 (CA INDEX NAME).


Absolute stereochemistry.



RN 786706-34-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran]-6'-ol, 1-(4-fluorophenyl)-1,3',4,4',4a,5',6,6',7,8-decahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-35-2 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[2H]pyran]-6'-ol, 1-(4-fluorophenyl)-3',4,4',4a,5',6,6',7-octahydro-4a-methyl-, (2'S,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786706-42-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan]-5'-ol, 1-(4-fluorophenyl)-

1,4,4',4a,5',6,7,8-octahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-43-2 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-1,3',4,4',4a,6,7,8-octahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-45-4 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-1,3',4,4',4a,6,7,8-octahydro-4a-methyl-4',4'-bis(phenylmethyl)-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-49-8 CAPLUS


CN Spiro[cyclopent[f]indazole-5(1H),2'(5'H)-furan]-5'-one,  
1-(4-fluorophenyl)-3',4,4',4a,6,7-hexahydro-4a-methyl-, (2'R,4aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 786706-50-1 CAPLUS  
CN Spiro[cyclopent[f]indazole-5(1H),2'(5'H)-furan]-5'-one,  
1-(4-fluorophenyl)-3',4,4',4a,6,7-hexahydro-4a-methyl-4',4'-di-2-propenyl-,  
(2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-56-7 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-phenyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-62-5 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-(5'H)-furan], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-01-5 CAPLUS

CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-07-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-acetic acid, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxo-, ethyl ester, (4aS,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-08-2 CAPLUS

CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 3'-[2-(1,3-dioxan-2-yl)ethyl]-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS,5S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-10-6 CAPLUS

CN Benzoic acid, 4-[(4aS,5S)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxospiro[5H-benz[f]indazole-5,5'-oxazolidin]-3'-yl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-14-0 CAPLUS


CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-acetic acid, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxo-, (4aS,5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-16-2 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-propanal,  
 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxo-, (4aS,5S)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-19-5 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-propanoic acid,  
 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxo-, (4aS,5S)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-23-1 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'S,4aS)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-24-2 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 786707-26-4 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-3'-(phenylmethyl)-,  
(4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-28-6 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-methyl-5'-thioxo-, (4'S,4aS)- (9CI) (CA INDEX


NAME)

Absolute stereochemistry.



RN 786707-52-6 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 786707-53-7 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolan]-8(4H)-one,  
1-(4-fluorophenyl)-1,4a,6,7-tetrahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 786707-54-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolan]-8-ol, 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a,8-dimethyl-, (4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-55-9 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H), 2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-56-0 CAPLUS

CN Spiro[cyclopent[f]indazole-5(6H), 2'-[1,3]dioxolan]-7(1H)-one, 1-(4-fluorophenyl)-4,4a-dihydro-4a-methyl-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-57-1 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H), 2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a-dihydro-4a,7-dimethyl-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-62-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-(phenylmethyl)-, (4'R,4aS,5'R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-06-3 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4'R,4aS,5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 571203-14-0P 614762-99-1P 786706-23-8P  
 786706-24-9P 786706-25-0P 786706-26-1P  
 786706-29-4P 786706-30-7P 786706-31-8P  
 786706-32-9P 786706-36-3P 786706-37-4P  
 786706-38-5P 786706-39-6P 786706-40-9P  
 786706-44-3P 786706-46-5P 786706-47-6P  
 786706-51-2P 786706-55-6P 786706-57-8P  
 786706-58-9P 786706-59-0P 786706-60-3P  
 786706-63-6P 786706-64-7P 786706-65-8P

786706-66-9P 786706-67-0P 786706-68-1P  
786706-69-2P 786706-70-5P 786706-71-6P  
786706-72-7P 786706-73-8P 786706-74-9P  
786706-75-0P 786706-76-1P 786706-77-2P  
786706-78-3P 786706-79-4P 786706-80-7P  
786706-81-8P 786706-82-9P 786706-83-0P  
786706-84-1P 786706-85-2P 786706-86-3P  
786706-90-9P 786706-96-5P 786706-97-6P  
786706-98-7P 786706-99-8P 786707-02-6P  
786707-03-7P 786707-04-8P 786707-05-9P  
786707-06-0P 786707-09-3P 786707-11-7P  
786707-12-8P 786707-13-9P 786707-15-1P  
786707-17-3P 786707-18-4P 786707-20-8P  
786707-21-9P 786707-22-0P 786707-25-3P  
786707-27-5P 786707-29-7P 786707-30-0P  
786707-31-1P 786707-32-2P 786707-33-3P  
786707-34-4P 786707-35-5P 786707-36-6P  
786707-37-7P 786707-38-8P 786707-39-9P  
786707-40-2P 786707-41-3P 786707-42-4P  
786707-43-5P 786707-44-6P 786707-45-7P  
786707-46-8P 786707-47-9P 786707-48-0P  
786707-49-1P 786707-50-4P 786707-51-5P  
786707-58-2P 786707-59-3P 786707-60-6P  
786707-61-7P 786707-63-9P 786707-64-0P  
786707-65-1P 786707-66-2P 786707-67-3P  
786707-68-4P 786707-69-5P 786707-70-8P  
786707-71-9P 786707-72-0P 786707-73-1P  
786707-74-2P 786707-75-3P 786707-76-4P  
786707-77-5P 786707-78-6P 786707-79-7P  
786707-80-0P 786707-81-1P 786707-82-2P  
786707-83-3P 786707-84-4P 786707-85-5P  
786707-86-6P 786707-87-7P 786707-88-8P  
786707-89-9P 786707-90-2P 786707-91-3P  
786707-94-6P 786707-95-7P 786707-96-8P  
786707-97-9P 786707-98-0P 786707-99-1P  
786708-00-7P 786708-01-8P 786708-02-9P  
786708-03-0P 786708-04-1P 786708-05-2P  
786708-07-4P 786708-08-5P 786708-09-6P  
786708-10-9P 786708-11-0P 786708-12-1P  
786708-13-2P 786708-14-3P 786708-15-4P  
786708-16-5P 786708-17-6P 786708-18-7P  
786708-19-8P 786708-20-1P 786708-21-2P  
786708-22-3P 786708-23-4P 786708-24-5P  
786708-25-6P 786708-26-7P 786708-27-8P  
786708-28-9P 786708-29-0P 786708-30-3P  
786708-31-4P 786708-32-5P 786708-33-6P  
786708-34-7P 786708-35-8P 786708-36-9P  
786708-37-0P 786708-38-1P 786708-39-2P  
786708-40-5P 786708-41-6P 786708-42-7P  
786708-43-8P 786708-44-9P 786708-45-0P  
786708-46-1P 786708-47-2P 786708-48-3P  
786708-49-4P 786708-50-7P 786708-51-8P  
786708-52-9P 786708-53-0P 786708-54-1P  
786708-55-2P 786708-56-3P 786708-58-5P  
786708-61-0P 786708-64-3P 786708-67-6P  
786708-70-1P 786708-73-4P 786708-75-6P  
786708-77-8P 786708-79-0P 786708-81-4P  
786708-83-6P 786708-85-8P 786709-54-4P  
786709-55-5P 786709-57-7P 786709-58-8P  
787619-78-7P 787619-79-8P 787619-80-1P  
787619-81-2P 787619-82-3P 787619-83-4P  
787619-84-5P 787619-85-6P 787619-86-7P  
787619-87-8P 787619-88-9P 787619-90-3P  
787619-92-5P 787619-93-6P 787619-95-8P


787619-97-0P 787619-99-2P 787620-00-2P  
787620-01-3P 787620-02-4P 787620-03-5P  
787620-04-6P 787620-05-7P 787620-06-8P  
787620-07-9P 787620-08-0P 787620-09-1P  
787620-10-4P 787620-11-5P 787620-12-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of pyrazoles bearing annulated spirocyclic hydronaphthalene  
derivs. as glucocorticoid receptor modulators)

RN 571203-14-0 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-methyl- (9CI) (CA INDEX NAME)



RN 614762-99-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-23-8 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-  
1,4,4',4a,5',6,7,8-octahydro-4',4a-dimethyl-, (2'R,4aS)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




RN 786706-24-9 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan]-4'-ol, 1-(4-fluorophenyl)-  
 1,4,4',4a,5',6,7,8-octahydro-4',4a-dimethyl-, (2'R,4aS)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 786706-25-0 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan]-5'(4'H)-one,  
 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-methylene-,  
 (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786706-26-1 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-  
 1,3',4,4',4a,6,7,8-octahydro-4a-methyl-4'-methylene-, (2'S,4aS)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 786706-29-4 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran], 1-(4-fluorophenyl)-  
1,3',4,4a,6,6',7,8-octahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786706-30-7 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran], 1-(4-fluorophenyl)-  
1,3',4,4a,6,6',7,8-octahydro-4a,5'-dimethyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-31-8 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran]-5'-carboxylic acid,  
1-(4-fluorophenyl)-1,3',4,4a,6,6',7,8-octahydro-4a-methyl-, methyl ester,  
(2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-32-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran]-5'-methanol, 1-(4-fluorophenyl)-1,3',4,4a,6,6',7,8-octahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-36-3 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran], 1-(4-fluorophenyl)-1,3',4,4',4a,5',6,6',7,8-decahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-37-4 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H), 2'-[2H]pyran], 1-(4-fluorophenyl)-3',4,4',4a,5',6,6',7-octahydro-4a-methyl-, (2'S,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-38-5 CAPLUS


CN Spiro[5H-benz[f]indazole-5, 2'-[2H]pyran], 1-(4-fluorophenyl)-1,3',4,4',4a,5',6,6',7,8-decahydro-4a,6'-dimethyl-, (2'R,4aS,6'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786706-39-6 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[2H]pyran], 6'-ethyl-1-(4-fluorophenyl)-  
 1,3',4,4',4a,5',6,6',7,8-decahydro-4a-methyl-, (2'R,4aS,6'S)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.




RN 786706-40-9 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[2H]pyran], 1-(4-fluorophenyl)-  
 3',4,4',4a,5',6,6',7-octahydro-4a,6'-dimethyl-, (2'S,4aS,6'S)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



RN 786706-44-3 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-  
 1,4,4',4a,5',6,7,8-octahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-46-5 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan]-5'-ol, 1-(4-fluorophenyl)-  
1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4',4'-bis(phenylmethyl)-,  
(2'R,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-47-6 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-  
1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4',4'-bis(phenylmethyl)-5'-(2-  
propenyl)-, (2'R,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-51-2 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'(5'H)-furan]-5'-one,  
1-(4-fluorophenyl)-3',4,4',4a,6,7-hexahydro-4a-methyl-4',4'-dipropyl-,  
(2'R,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-55-6 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2' (5'H)-furan], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-phenyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-57-8 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2' (5'H)-furan], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-58-9 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2' (5'H)-furan], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-59-0 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'(5'H)-furan], 1,4'-bis(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-60-3 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'(5'H)-furan], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-(phenylmethyl)-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-63-6 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'(5'H)-furan], 4'-ethyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786706-64-7 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-  
 1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4'-phenyl-, (2'R,4'S,4aS) - (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 786706-65-8 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'(5'H)-furan]-5'-one,  
 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4aS) - (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.




RN 786706-66-9 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan], 1-(4-fluorophenyl)-  
 4,4',4a,5',6,7-hexahydro-4a-methyl-4',4'-dipropyl-, (2'R,4aS) - (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.




RN 786706-67-0 CAPLUS  
CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan]-5'-ol,  
1-(4-fluorophenyl)-4,4',4a,5',6,7-hexahydro-4a-methyl-4',4'-dipropyl-,  
(2'R,4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-68-1 CAPLUS  
CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan], 1-(4-fluorophenyl)-  
4,4',4a,5',6,7-hexahydro-4a-methyl-4',4'-di-2-propenyl-, (2'R,4aS)-(9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 786706-69-2 CAPLUS  
CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan]-5'-ol,

1-(4-fluorophenyl)-4,4',4a,5',6,7-hexahydro-4a-methyl-4',4'-di-2-propenyl-,  
(2'R,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-70-5 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan], 1-(4-fluorophenyl)-  
4,4',4a,5',6,7-hexahydro-4',4',4a-trimethyl-, (2'R,4aS)-(9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 786706-71-6 CAPLUS


CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan]-5'-ol,  
1-(4-fluorophenyl)-4,4',4a,5',6,7-hexahydro-4',4',4a-trimethyl-,  
(2'R,4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786706-72-7 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'(5'H)-furan]-5'-one,  
 1-(4-fluorophenyl)-3',4,4',4a,6,7-hexahydro-4',4',4a-trimethyl-,  
 (2'R,4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786706-73-8 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan], 1-(4-fluorophenyl)-  
 4,4',4a,5',6,7-hexahydro-4a-methyl-, (2'R,4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786706-74-9 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'(3'H)-furan]-5'-ol,  
 1-(4-fluorophenyl)-4,4',4a,5',6,7-hexahydro-4a-methyl-, (2'R,4aS)-(9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-75-0 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 5'-ethyl-1-(4-fluorophenyl)-  
1,4,4',4a,5',6,7,8-octahydro-4a-methyl-, (2'S,4aS,5'S)- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 786706-76-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 5'-ethyl-1-(4-fluorophenyl)-  
1,4,4',4a,5',6,7,8-octahydro-4a-methyl-, (2'S,4aS,5'R)- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 786706-77-2 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-  
1,4,4',4a,5',6,7,8-octahydro-4a-methyl-5'-phenyl-, (2'S,4aS,5'S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 786706-78-3 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-  
 1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4',4',5'-tri-2-propenyl-,  
 (2'R,4aS) - (9CI). (CA INDEX NAME)

Absolute stereochemistry.




RN 786706-79-4 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-  
 1,4,4',4a,5',6,7,8-octahydro-4',4',4a-trimethyl-, (2'R,4aS) - (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



RN 786706-80-7 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-  
 1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4',4'-bis(phenylmethyl)-,  
 (2'R,4aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-81-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan], 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4',4'-di-2-propenyl-, (2'R,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-82-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan]-5'-ol, 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4',4',4a-trimethyl-, (2'R,4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786706-83-0 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'(3'H)-furan]-5'-ol, 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-4',4'-di-2-propenyl-, (2'R,4aS)-(9CI) (CA INDEX NAME)

(9CI) (CA INDEX NAME).


Absolute stereochemistry.



RN 786706-84-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-(3'H)-furan], 1-(4-fluorophenyl)-1,4,4',4a,5',6,7,8-octahydro-4a-methyl-5'-(2-propenyl)-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-85-2 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-1,3',4,4',4a,6,7,8-octahydro-4',4',4a-trimethyl-, (2'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-86-3 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-(5'H)-furan]-5'-one, 1-(4-fluorophenyl)-1,3',4,4',4a,6,7,8-octahydro-4a-methyl-4',4'-di-2-propenyl-, (2'R,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-90-9 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-pyrrolidin]-5'-one, 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786706-96-5 CAPLUS


CN Spiro[cyclopent[f]indazole-5(1H),3'-pyrrolidine], 1'-(ethylsulfonyl)-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (3'S,4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786706-97-6 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),3'-pyrrolidine], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4a-methyl-1'-(phenylsulfonyl)-, (3'S,4aS)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



RN 786706-98-7 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,3'-pyrrolidine], 1'-(ethylsulfonyl)-1-(4-  
 fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (3'S,4aS)- (9CI) (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 786706-99-8 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,3'-pyrrolidine], 1-(4-fluorophenyl)-


1,4,4a,6,7,8-hexahydro-4a-methyl-1'-(phenylsulfonyl)-, (3'S,4aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 786707-02-6 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-methyl-3'-(phenylmethyl)-, (4aS,5S)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



RN 786707-03-7 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-, (4aS,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-04-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-methyl-3'-(2-propenyl)-, (4aS,5S)- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 786707-05-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-methyl-3'-(1-methylethyl)-, (4aS,5S)- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 786707-06-0 CAPLUS


CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-3'-(2-methoxyethyl)-4a-methyl-, (4aS,5S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 786707-09-3 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 3'-acetyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-11-7 CAPLUS  
 CN Benzoic acid, 4-[(4aS,5S)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxospiro[5H-benz[f]indazole-5,5'-oxazolidin]-3'-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-12-8 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-3'-phenyl-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-13-9 CAPLUS  
 CN Benzoic acid, 3-[(4aS,5S)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxospiro[5H-benz[f]indazole-5,5'-oxazolidin]-3'-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-15-1 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-acetamide, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxo-N-phenyl-, (4aS,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-17-3 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 3'-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-

, (4aS,5S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-18-4 CAPLUS

CN Spiro[5H-benz[f]indazole-5,5'-oxazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3'-(3-hydroxypropyl)-4a-methyl-, (4aS,5S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-20-8 CAPLUS


CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-propanamide, N-cyano-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxo-, (4aS,5S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-21-9 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-propanamide,  
 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-N-(methylsulfonyl)-2'-  
 oxo-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-22-0 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,5'-oxazolidine]-3'-propanamide,  
 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2'-oxo-N-  
 (phenylsulfonyl)-, (4aS,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-25-3 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-, (4'R,4aS)-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-27-5 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-1',4a-dimethyl-3'-(phenylmethyl)-  
, (4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-29-7 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'S,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-30-0 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-, (4'S,4aS)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-31-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-1'-(phenylmethyl)-  
, (4'R,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-32-2 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-1',3',4a-trimethyl-, (4'R,4aS)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-33-3 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-1'-(2-propenyl)-,  
(4'R,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-34-4 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-1'-(phenylmethyl)-  
, (4'S,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-35-5 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-1',3',4a-trimethyl-, (4'S,4aS)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-36-6 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,

1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-1'-(2-propenyl)-,  
(4'S,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-37-7 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-1'-propanoic acid,  
1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2',5'-dioxo-3'-  
(phenylmethyl)-, (4'R,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-38-8 CAPLUS


CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-3'-propanoic acid,  
1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-2',5'-dioxo-,  
(4'R,4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-39-9 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
 3'-[2-(1,3-dioxan-2-yl)ethyl]-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-  
 methyl-, (4'R,4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-40-2 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-1'-propanoic acid,  
 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-2',5'-dioxo-,  
 (4'S,4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-41-3 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
 1'-[2-(1,3-dioxan-2-yl)ethyl]-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-  
 3',4a-dimethyl-, (4'S,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-42-4 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-1',3'-di-2-propenyl-,  
(4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-43-5 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidine]-2',5'-dione,  
1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-1',3'-  
bis(phenylmethyl)-, (4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-44-6 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-methyl-3'-(phenylmethyl)-5'-thioxo-, (4'R,4aS)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-45-7 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-5'-thioxo-, (4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-46-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-3'-(2-propenyl)-5'-thioxo-, (4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-47-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-5'-thioxo-, (4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-48-0 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-3'-(phenylmethyl)-, (4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-49-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-50-4 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-1',3',4a-trimethyl-, (4'S,4aS)- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 786707-51-5 CAPLUS

CN Spiro[5H-benz[f]indazole-5,4'-imidazolidin]-2'-one, 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-3',4a-dimethyl-, (4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-58-2 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4'-(methoxymethyl)-4a-methyl-, (2'R,4'R,4aS)- (9CI).  
(CA INDEX NAME)

Absolute stereochemistry.




RN 786707-59-3 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4'-(methoxymethyl)-4a-methyl-, (2'R,4'S,4aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 786707-60-6 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4'-(methoxymethyl)-4a-methyl-, (2'S,4'R,4aS)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 786707-61-7 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4'-(methoxymethyl)-4a-methyl-, (2'S,4'S,4aS)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.




RN 786707-63-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-, (4'R,4aS,5'R)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 786707-64-0 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethyl-1-(4-  
fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl- (9CI) (CA INDEX NAME)




RN 786707-65-1 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethyl-1-(4-  
fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 786707-66-2 CAPLUS  
CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-dipropyl- (9CI) (CA INDEX NAME)



RN 786707-67-3 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-dipropyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-68-4 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-dibutyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786707-69-5 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 4'-(1-ethylpropyl)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-6'-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 786707-70-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786707-71-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-di-1-propenyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 786707-72-0 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane]-4',5'-dicarboxylic acid, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, dimethyl ester,

(4'S,4aS,5'S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-73-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-furo[3,4-d][1,3]dioxol]-4'-(3'aH)-one,  
1-(4-fluorophenyl)-1,4,4a,6,6',6'a,7,8-octahydro-4a-methyl-, (3'aR,6'aR)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-74-2 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]benzodioxole], 1-(4-fluorophenyl)-  
1,3'a,4,4',4a,5',6,6',7,7',7'a,8-dodecahydro-4a-methyl-, (3'aR,4aS,7'aR)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-75-3 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'-naphtho[1,2-d][1,3]dioxole],  
1-(4-fluorophenyl)-1,3'a,4,4',4a,5',6,7,8,9'b-decahydro-4a-methyl-,  
(3'aR,9'bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 786707-76-4 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'-naphtho[2,3-d][1,3]dioxole],  
1-(4-fluorophenyl)-1,3'a,4,4',4a,6,7,8,9',9'a-decahydro-4',4',4a,9',9'-  
pentamethyl- (9CI) (CA INDEX NAME)



RN 786707-77-5 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-dicyclohexyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-78-6 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-diphenyl-, (4'R,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-79-7 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-bis(2-chlorophenyl)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-80-0 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',5'-bis(methoxymethyl)-4a-methyl-, (4'R,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-81-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-bis[(phenylmethoxy)methyl]-, (4'R,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-82-2 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-bis[[4-chlorophenyl)methoxy]methyl]-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-83-3 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',4a-dimethyl-, (4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-84-4 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-85-5 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-propyl-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-86-6 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-(1,1-dimethylethyl)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-87-7 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-88-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'S,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-89-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-90-2 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (2'S,4'S,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-91-3 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4'-(5-hexenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-94-6 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-(ethoxymethyl)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-95-7 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-[(2-propenyloxy)methyl]-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786707-96-8 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-methyl-4'-[(methylthio)methyl]-, (4aS)-(9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 786707-97-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dithiolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-methyl- (9CI) (CA INDEX NAME)




RN 786707-98-0 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dithiolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl- (9CI) (CA INDEX NAME)




RN 786707-99-1 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-  
 1,4,4a,6,7,8-hexahydro-4a-methyl- (9CI) (CA INDEX NAME)




RN 786708-00-7 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-  
 1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-01-8 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-  
 1,4,4a,6,7,8-hexahydro-4a,5',5'-trimethyl- (9CI) (CA INDEX NAME)



RN 786708-02-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a,5',5'-trimethyl-, (4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 786708-03-0 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4',4a,6'-trimethyl-, (4'S,4aS,6'S)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 786708-04-1 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dithiane], 1-(4-fluorophenyl)-  
 1,4,4a,6,7,8-hexahydro-4a-methyl- (9CI) (CA INDEX NAME)



RN 786708-05-2 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4'S,4aS,5'S)- (9CI) (CA INDEX  
 NAME)


Absolute stereochemistry.



RN 786708-07-4 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1'-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4',5'-di-(1E)-1-propenyl-, (4'R,4aS,5'R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 786708-08-5 CAPLUS

CN 2-Propenoic acid, 3,3'-[(4'S,4aS,5'S)-1-(4-fluorophenyl)-4,4a,6,7-tetrahydrospiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane]-4',5'-diyl]bis-, dimethyl ester, (2E,2'E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 786708-09-6 CAPLUS

CN Spiro[1,3-benzodioxole-2,5'(1'H)-cyclopent[f]indazole], 1'-(4-fluorophenyl)-3a,4,4',4'a,5,6,6',7,7',7a-decahydro-4'a-methyl-, (3aR,4'aS,7aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-10-9 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4',5'-diphenyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-11-0 CAPLUS


CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',5'-bis(methoxymethyl)-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-12-1 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4',4a-dimethyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-13-2 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4',4a-dimethyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-14-3 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-  
 fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4'S,4aS)- (9CI) (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 786708-15-4 CAPLUS

CN Spiro[cyclopent [f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'S,4'S,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-16-5 CAPLUS

CN Spiro[cyclopent [f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-17-6 CAPLUS

CN Spiro[cyclopent [f]indazole-5(1H),2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-18-7 CAPLUS

CN Spiro[cyclopent [f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-

4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'S,4'R,4aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-19-8 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'R,4'R,4aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-20-1 CAPLUS


CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'R,4'S,4aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-21-2 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4a-methyl-4'-phenyl-, (2'S,4'S,4aS)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 786708-22-3 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4',4a-dimethyl-4'-phenyl-, (2'R,4'S,4aS)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



RN 786708-23-4 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4',4a-dimethyl-4'-phenyl-, (2'R,4'R,4aS)- (9CI) (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 786708-24-5 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-4'-phenyl-, (2'S,4'S,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-25-6 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-4'-phenyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-26-7 CAPLUS


CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4'-(methoxymethyl)-4a-methyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-27-8 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4'-(methoxymethyl)-4a-methyl-, (2'R,4'S,4aS)-(9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-28-9 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4'-(methoxymethyl)-4a-methyl-, (2'S,4'R,4aS)-(9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 786708-29-0 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4'-(methoxymethyl)-4a-methyl-, (2'S,4'S,4aS)-(9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-30-3 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4aS)-(9CI) (CA INDEX NAME).


Absolute stereochemistry.



RN 786708-31-4 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-, (4'R,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-32-5 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-, (4'S,4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-33-6 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6'-trimethyl-, (4'S,4aS,6'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-34-7 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H), 2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a,5',5'-trimethyl-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-35-8 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H), 2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4',4a,6'-tetramethyl-, (2'R,4aS,6'R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-36-9 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H), 2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4',4a,6'-tetramethyl-, (2'S,4aS,6'R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-37-0 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H), 2'-[1,3]dithiane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-38-1 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H), 2'-[1,3]dithiane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a-dimethyl-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-39-2 CAPLUS

CN Spiro[5H-benz[f]indazole-5, 2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-(phenylmethyl)-, (4'S,4aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-40-5 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-(phenylmethyl)-, (2'S,4'S,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-41-6 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4'-ethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-(phenylmethyl)-, (2'R,4'S,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-42-7 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',6'-dimethyl-4a-(phenylmethyl)-, (4'S,4aS,6'S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-43-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-1,4,4a,6-tetrahydro-4a,8-dimethyl-, (4'R,4aS,5'R)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 786708-44-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6-tetrahydro-4a,8-dimethyl-4',5'-diphenyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-45-0 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 4',5'-diethyl-1-(4-

fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-, stereoisomer (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-46-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-(phenylmethyl)-, (4'R,4aS,5'R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-47-2 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-1-phenyl-, (4'R,4aS,5'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-48-3 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-1-(4-pyridinyl)-, (4'R,5'R)-(9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 786708-49-4 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1-(3-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-50-7 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-  
1,4,4a,6,7,8-hexahydro-4a-methyl-1-(phenylmethyl)-, (4'R,4aS,5'R)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 786708-51-8 CAPLUS

CN 'Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-cyclopentyl-4',5'-  
diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 786708-52-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-cyclohexyl-4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-53-0 CAPLUS

CN Acetamide, N-[4-(4',5'-diethenyl-1,4,4',4a,5',6,7,8-octahydro-4a-methylspiro[5H-benz[f]indazole-5,2'-[1,3]dioxolan]-1-yl)phenyl]-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-54-1 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-chlorophenyl)-4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-55-2 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-  
 1,4,4a,6,7,8-hexahydro-4a-methyl-1-[4-(1-methylethoxy)phenyl]-,  
 (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-56-3 CAPLUS  
 CN Carbamic acid, dimethyl-, 4-[(4'R,4aS,5'R)-4',5'-diethenyl-  
 1,4,4',4a,5',6,7,8-octahydro-4a-methylspiro[5H-benz[f]indazole-5,2'-  
 [1,3]dioxolan]-1-yl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-58-5 CAPLUS  
 CN Propanoic acid, 2,2-dimethyl-, 4-[(4'R,4aS,5'R)-4',5'-diethenyl-  
 1,4,4',4a,5',6,7,8-octahydro-4a-methylspiro[5H-benz[f]indazole-5,2'-  
 [1,3]dioxolan]-1-yl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-61-0 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(3,4-dichlorophenyl)-4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'R,4aS,5'R)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-64-3 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-1-(4-methoxyphenyl)-4a-methyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-67-6 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-1-(4-methylphenyl)-, (4'R,4aS,5'R)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-70-1 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1,4,4a,6,7,8-hexahydro-4a-methyl-1-[4-(trifluoromethyl)phenyl]-, (4'R,4aS,5'R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-73-4 CAPLUS  
 CN Benzoic acid, 4-[(4'R,4aS,5'R)-4',5'-diethenyl-1,4,4',4a,5',6,7,8-octahydro-4a-methylspiro[5H-benz[f]indazole-5,2'-[1,3]dioxolan]-1-yl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786708-75-6 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-cyclopentyl-1,4,4a,6,7,8-hexahydro-4a-methyl- (9CI) (CA INDEX NAME)




RN 786708-77-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1,4,4a,6,7,8-hexahydro-1-(4-methoxyphenyl)-4a-methyl- (9CI) (CA INDEX NAME)




RN 786708-79-0 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1,4,4a,6,7,8-hexahydro-4a-methyl-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 786708-81-4 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1,4,4a,6,7,8-hexahydro-4a-methyl-1-phenyl- (9CI) (CA INDEX NAME)



RN 786708-83-6 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-1-phenyl-, (4'R,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786708-85-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-1-(4-pyridinyl)-, (4'R,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786709-54-4 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-phenyl-, (2'R,4'R,4aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 786709-55-5 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-phenyl-, (2'S,4'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786709-57-7 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 1,4,4a,6,7,8-hexahydro-4a-methyl-4'-phenyl-, (2'S,4'S,4aS)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.




RN 786709-58-8 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 1,4,4a,6,7,8-hexahydro-4a-methyl-4'-phenyl-, (2'R,4'S,4aS)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



RN 787619-78-7 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-, (4'α,5'β)- (9CI)  
 (CA INDEX NAME)


Relative stereochemistry.



RN 787619-79-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-, (4'R,4aS,5'S)- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 787619-80-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-, (4'S,4aR,5'R)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 787619-81-2 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4',4a,5'-trimethyl-, (4'S,4aS,5'S)- (9CI) (CA  
INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 787619-82-3 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'α,5'α)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 787619-83-4 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-dipropyl-, (4'α,5'α)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 787619-84-5 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'α,5'α)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 787619-85-6 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-di-1-propynyl-, (4'R,4aS,5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787619-86-7 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane]-4',5'-dicarboxylic acid, 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, dimethyl ester, (4'R,4aS,5'R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787619-87-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[6H]cyclopenta[1,3]dioxole],  
1-(4-fluorophenyl)-1,3'a,4,4',4a,5',6,6'a,7,8-decahydro-4a-methyl-,  
(3'aR,6'aS)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 787619-88-9 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[6H]cyclopenta[1,3]dioxole],  
1-(4-fluorophenyl)-1,3'a,4,4',4a,5',6,6'a,7,8-decahydro-4a-methyl-,  
(3'aR,4aS,6'aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787619-90-3 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]benzodioxole], 1-(4-fluorophenyl)-  
1,3'a,4,4',4a,5',6,6',7,7',7'a,8-dodecahydro-4a-methyl-, (3'aR,4aS,7'aS)-  
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 787619-92-5 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-diphenyl-, (4' $\alpha$ ,5' $\alpha$ )-  
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 787619-93-6 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-methyl-4',5'-diphenyl-, (4'R,4aS,5'R)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 787619-95-8 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-bis(2-chlorophenyl)-1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4'S,5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787619-97-0 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',5'-bis(methoxymethyl)-4a-methyl-, (4'S,5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787619-99-2 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4',5'-bis(methoxymethyl)-4a-methyl-, (4'S,4aS,5'S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787620-00-2 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4',4a,6'-trimethyl-, (4'R,4aS,6'R)- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 787620-01-3 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4',4a,6'-trimethyl-, (4'R,4aS,6'S)- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 787620-02-4 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4'R,4aS,5'R)- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 787620-03-5 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4aS,2' $\alpha$ ,4' $\alpha$ ,5'.alpha.) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787620-04-6 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4aS,2' $\alpha$ ,4' $\beta$ ,5' $\beta$ ) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787620-05-7 CAPLUS

CN Spiro[4H-cyclopenta-1,3-dioxole-2,5'(1'H)-cyclopent[f]indazole], 1-(4-fluorophenyl)-3'a,4,4',4a,5',6,6'a,7-octahydro-4a-methyl-, (4aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787620-06-8 CAPLUS

CN Spiro[1,3-benzodioxole-2,5'-(1'H)-cyclopent[f]indazole],  
1'-(4-fluorophenyl)-3a,4,4',4'a,5,6,6',7,7',7a-decahydro-4'a-methyl-,  
(3aS,4'aS,7aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787620-07-9 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
4,4a,6,7-tetrahydro-4',5'-bis(methoxymethyl)-4a-methyl-, (4'S,4aS,5'S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787620-08-0 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dithiolane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787620-09-1 CAPLUS

CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6'-trimethyl-, (4'R,4aS,6'R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 787620-10-4 CAPLUS


CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dioxane], 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4',4a,6'-trimethyl-, (4'R,4aS,6'S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 787620-11-5 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 4',5'-diethenyl-  
 1,4,4a,6,7,8-hexahydro-4a-methyl-1-phenyl-, (4'R,5'R)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



RN 787620-12-6 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[6H]cyclopenta[1,3]dioxole],  
 1,3'a,4,4',4a,5',6,6'a,7,8-decahydro-4a-methyl-1-phenyl-, (3'aR,4aS,6'aS)-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 790220-33-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of pyrazoles bearing annulated spirocyclic hydronaphthalene  
 derivs. as glucocorticoid receptor modulators)  
 RN 790220-33-6 CAPLUS  
 CN Spiro[cyclopent[f]indazole-5(1H),2'-[1,3]dithiolane], 1-(4-fluorophenyl)-  
 4,4a,6,7-tetrahydro-4',4a,5'-trimethyl-, (4'R,4aS,5'S)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



IT 786706-54-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazoles bearing annulated spirocyclic hydronaphthalene derivs. as glucocorticoid receptor modulators)

RN 786706-54-5 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-(5'H)-furan], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-4'-(tributylstannyl)-, (2'R,4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:740124 CAPLUS

DN 141:260743

TI Preparation of cyclopent[f]indazole and benz[f]indazole derivatives selective non-steroidal glucocorticoid receptor modulators

IN Ali, Amjad; Beresis, Richard; Colletti, Steven L.; Graham, Donald W.; Tata, James R.; Thompson, Christopher F.

PA Merck & Co. Inc., USA

SO PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004075840	A2	20040910	WO 2004-US5199	20040220
	WO 2004075840	A3	20050203		

WO 2004075840 A9 20050804

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI  
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004216182 A1 20040910 AU 2004-216182 20040220  
CA 2516684 A1 20040910 CA 2004-2516684 20040220  
EP 1599201 A2 20051130 EP 2004-713398 20040220  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
JP 2006518752 T 20060817 JP 2006-503780 20040220  
US 2006074120 A1 20060406 US 2005-544899 20050808  
PRAI US 2003-450811P P 20030225  
WO 2004-US5199 W 20040220

OS MARPAT 141:260743  
GI



AB Title compds. represented by the formula I [wherein J = NR<sub>1</sub>, CR<sub>1</sub>R<sub>2</sub>; K = NR<sub>3</sub>, CR<sub>3</sub>R<sub>4</sub>; L = NR<sub>5</sub>, CR<sub>5</sub>R<sub>6</sub>; X = hydroxy, alkoxy, carbamoyl, etc.; R<sub>1</sub>-R<sub>6</sub> = independently H, halo, (cyclo)alkyl, etc.; R<sub>7</sub> = H, hydroxy, alkoxy, aryl, etc.; R<sub>8</sub> = (cyclo)alkyl, alkenyl, alkynyl, etc.; R<sub>9</sub>, R<sub>10</sub> = independently halo, hydroxy, alkyl, alkenyl, alkoxy; n = 0-2; and pharmaceutically acceptable salts or hydrates thereof] were prepared as selective non-steroidal glucocorticoid receptor modulators. For example, II was given in a multi-steps synthesis starting from 1-(4-fluorophenyl)-4,4a,6,7-tetrahydro-4a-methyl-cyclopent[f]indazol-5(1H)-one reacting with phenylethylnymagnesium bromide. I showed affinity of glucocorticoid receptor with IC<sub>50</sub> values between 10 μM and 1 nM. Thus, I and their pharmaceutical compns. are useful for the treatment of a variety of autoimmune and inflammatory diseases or conditions.

IT 614762-99-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of cyclopent[f]indazol-5-yl and benz[f]indazol-5-yl derivs. as selective non-steroidal glucocorticoid receptor modulators)

RN 614762-99-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007-ACS-on-STN

AN 2004:270010 CAPLUS

DN 140:287380

TI Preparation of octahydro-2-H-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators for the treatment of autoimmune and inflammatory conditions

IN Ali, Amjad; Aster, Susan D.; Balkovec, James M.; Graham, Donald W.; Hunt, Julianne A.; Kallashi, Florida; Sinclair, Peter J.; Tata, James R.; Taylor, Gayle E.; Goulet, Joung L.

PA Merck & Co., Inc., USA


SO PCT Int. Appl., 170 pp.  
CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026248	A2	20040401	WO 2003-US29494	20030917
	WO 2004026248	A3	20040715		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2499150	A1	20040401	CA 2003-2499150	20030917
	AU 2003270783	A1	20040408	AU 2003-270783	20030917
	EP 1542996	A2	20050622	EP 2003-752495	20030917
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2006503107	T	20060126	JP 2004-568945	20030917
	US 2005245588	A1	20051103	US 2005-527615	20050311
PRAI	US 2002-412231P	P	20020920		
	US 2003-476079P	P	20030605		
	WO 2003-US29494	W	20030917		
OS	MARPAT 140:287380				
GI					



I



II

AB Octahydro-2-H-naphtho[1,2-f]indole-4-carboxamide derivs. I (X = CO, NHCO, CONH, NH, CH<sub>2</sub>NH; R<sub>1</sub>, R<sub>2</sub> = H, alkyl, alkenyl, cycloalkyl, alkoxy, aryl; R<sub>3</sub> = alkyl, alkoxy, acid, halogen substituted alkyl; R<sub>4</sub> = alkyl, alkenyl, cycloalkoxy, alkoxy, aryl) were prepared as selective glucocorticoid receptor modulators for the treatment of autoimmune and inflammatory conditions. Thus, (S)-Wieland-Miescher ketone was protected as the ketal using p-toluene sulfonic acid and ethylene glycol and then treated with Et formate to give the hydroxymethylene ketal derivative. The hydroxymethylene was dissolved in acetic acid and reacted with p-fluorophenyl hydrazine hydrochloride to give II. The ketal of II was converted to the ketone using 6N HCl, and the resulting ketone transformed into the triflate. The triflate was treated with tributylvinyl tin and PPh<sub>3</sub> to give the corresponding coupling product. Treatment with ethyl-4,4,4-trifluorocrotonate followed by dropwise addition of BCl<sub>3</sub> gave the target I (R<sub>1</sub> = CF<sub>3</sub>, R<sub>2</sub>, R<sub>3</sub> = H, X = CO, R<sub>4</sub> = OEt),.

IT 614762-99-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of octahydronaphthoindole-4-carboxamide derivs. as selective glucocorticoid receptor modulators for the treatment of autoimmune and inflammatory conditions)


RN 614762-99-1 CAPLUS

CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry..




TI Novel N-Arylpyrazolo[3,2-c]-Based Ligands for the Glucocorticoid Receptor:  
 Receptor Binding and in Vivo Activity  
 AU Ali, Amjad; Thompson, Christopher F.; Balkovec, James M.; Graham, Donald  
 W.; Hammond, Milton L.; Quraishi, Nazia; Tata, James R.; Einstein, Monica;  
 Ge, Lan; Harris, Georgianna; Kelly, Terri M.; Mazur, Paul; Pandit, Shilpa;  
 Santoro, Joseph; Sitlani, Ayesha; Wang, Chuanlin; Williamson, Joanne;  
 Miller, Douglas K.; Thompson, Chris M.; Zaller, Dennis M.; Forrest,  
 Michael J.; Carballo-Jane, Ester; Luell, Silvi  
 CS Departments of Medicinal Chemistry, Metabolic Disorders Immunology and  
 Pharmacology, Merck Research Laboratories, Rahway, NJ, 07065, USA  
 SO Journal of Medicinal Chemistry (2004), 47(10), 2441-2452  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 141:7063  
 GI



AB A novel series of selective ligands for the human glucocorticoid receptor  
 (hGR) are described. Preliminary structure-activity relationships were  
 focused on substitution at C-1 and indicated a preference for 3-, 4-, and  
 5-substituted aromatic and benzylic groups. The resulting analogs, e.g., I  
 [R = OH, R1 = 3,4,5-MeO(F2)C6H2, CH2C6H4F-4], exhibited excellent affinity  
 for hGR (IC50 1.9 nM and 2.8 nM, resp.) and an interesting partial agonist  
 profile in functional assays of transactivation (tyrosine  
 aminotransferase, TAT, and glutamine synthetase, GS) and transrepression  
 (IL-6). The most potent compds. were I [R = 4-FC6H4, 2-thienyl, R1 = OH].  
 These candidates showed highly efficacious IL-6 inhibition vs.  
 dexamethasone. I [R = 2-thienyl, R1 = OH] was evaluated in vivo in the  
 mouse LPS challenge model and showed an ED50 = 4.0 mg/kg, compared to 0.5  
 mg/kg for prednisolone in the same assay.  
 IT 614762-99-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and glucocorticoid receptor binding of  
 [aryl(hydroxy)methyl]naphthopyrazoles)  
 RN 614762-99-1 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-  
 1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:836773 CAPLUS

DN 139:323524

TI Preparation of 1H-Benzo[f]indazol-5-yl derivatives as selective  
glucocorticoid receptor modulators

IN Ali, Amjad; Balkovec, James M.; Graham, Donald W.; Thompson, Christopher  
F.; Quraishi, Nazia

PA Merck & Co., Inc., USA



SO PCT Int. Appl., 233 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086294	A2	20031023	WO 2003-US10867	20030408
	WO 2003086294	A3	20040715		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2481320	A1	20031023	CA 2003-2481320	20030408
	AU 2003221706	A1	20031027	AU 2003-221706	20030408
	EP 1496892	A2	20050119	EP 2003-718285	20030408
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005528385	T	20050922	JP 2003-583321	20030408
	US 2005256315	A1	20051117	US 2005-508897	20050428
PRAI	US 2002-371948P	P	20020411		
	WO 2003-US10867	W	20030408		
OS	MARPAT 139:323524				
GI					




AB Benzindazoles I [ $n = 0-2$ ; J, K, L = (un)substituted  $\text{CH}_2$ , NH; X = bond, CO, (un)substituted NH, NHCO, 1,1-cyclopropanediyl; R1, R2 = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, aryl, aralkyl, heterocyclic, aryloxy, aroyloxy, OH; R3 = H, (un)substituted OH, alkyl, aryl, aralkyl; Y = H, (un)substituted OH, SH, S(O)H,  $\text{SO}_2\text{H}$ ,  $\text{CH}_2$ ,  $\text{NH}_2$ ,  $\text{SO}_2\text{NH}_2$ ,  $\text{CO}_2\text{H}$ ,  $\text{NO}_2$ , acyl, CN, halogen; and the carbocyclic rings may be further substituted] were prepared for use as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions (no data). Thus, Wieland-Miescher ketone was ketalized, hydroxymethylenated, cyclized with 4- $\text{FC}_6\text{H}_4\text{NHNH}_2$ , deketalized, treated with  $\text{Ph}_3\text{P}+\text{CH}_2\text{OMe Cl}^-$ , and subjected to Grignard reaction with 4- $\text{FC}_6\text{H}_4\text{MgCl}$  to give the benzindazole II.

IT 614762-99-1P 614763-23-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of 1H-benzo[f]indazol-5-yl derivs. as selective glucocorticoid receptor modulators)

RN 614762-99-1 CAPLUS


CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614763-23-4 CAPLUS  
 CN Spiro[5H-benz[f]indazole-5,2'-oxirane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl-, (4aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



~~L8 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN~~

AN 2003:590999 CAPLUS

DN 139:149523

TI Preparation of non-steroidal ligands for the glucocorticoid receptor

IN Scanlan, Thomas S.; Shah, Nilesh

PA The Regents of the University of California, USA

SO PCT Int. Appl., 70 pp.



CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003061651	A1	20030731	WO 2003-US1997	20030122
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2473886	A1	20030731	CA 2003-2473886	20030122
	US 2003176478	A1	20030918	US 2003-350260	20030122
	US 6831093	B2	20041214		
	EP 1467730	A1	20041020	EP 2003-710722	20030122
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005523254	T	20050804	JP 2003-561595	20030122
	US 2005054700	A1	20050310	US 2004-972250	20041022
PRAI	US 2002-351484P	P	20020122		
	US 2002-373757P	P	20020417		
	US 2003-350260	A3	20030122		
	WO 2003-US1997	W	20030122		
OS	MARPAT 139:149523				
GI					




- AB Naphthoheterocycles I [A, B, D = C, N, O, S, at least one of A, B, and D being N, O, or S; W = C, O, N, S; R1 = H, (un)substituted alkyl, acyl, NH2, CO2H, aralkyl, CONH2, heterocyclic, CN, halogen; R2, R3, R5, R6, R6', R7 = H, (un)substituted alkyl, acyl, alkoxy, NH2, sulfonyl, sulfinyl, SH, CO2H, aralkyl, CONH2, heterocyclic, OH, CN, halogen; R2', R3', R5', R7', R8 = absent or H, (un)substituted alkyl, acyl, NH2, alkoxy, sulfonyl, sulfinyl, SH, aralkyl, CONH2, heterocyclic, CN, halogen; R4 = absent or H, (un)substituted alkyl, acyl, NH2, CO2H, aralkyl, CONH2, heterocyclic, CN, halogen; R9 = absent or H, (un)substituted alkyl, alkoxy, NH2, CO2H, CN, halogen, O, S, OH; R10 = absent or H, (un)substituted alkyl, acyl, CO2H, aralkyl, aryl, cycloalkyl, heterocyclic; R2R10 = atoms required to form a ring; R11, R12 = H, (un)substituted alkyl, acyl, NH2, alkoxy, sulfonyl, sulfinyl, SH, aryl, aralkyl, CONH2, heterocyclic, OH, CN, halogen, O, S] were prepared as non-steroidal ligands for the glucocorticoid receptor. They are useful for treating or preventing diseases (e.g., obesity, diabetes, depression, neurodegeneration of an inflammatory disease) associated with glucocorticoid binding to the glucocorticoid receptor. Thus, Wieland-Miescher ketone was converted to its 5-ethyleneketal, hydroxymethylenated, and cyclized with 4-FC6H4NHNH2 to give the benzindazolone II which had IC50 of 436 nM in a glucocorticoid receptor binding test.
- IT 571203-14-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of non-steroidal ligands for the glucocorticoid receptor)
- RN 571203-14-0 CAPLUS
- CN Spiro[5H-benz[f]indazole-5,2'-[1,3]dioxolane], 1-(4-fluorophenyl)-1,4,4a,6,7,8-hexahydro-4a-methyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


ANSWER 18 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1991:185370 CAPLUS  
DN 114:185370  
TI Receptor-based design of novel dihydrofolate reductase inhibitors:  
benzimidazole and indole derivatives  
AU Ohemeng, Kwasi A.; Roth, Barbara  
CS Wellcome Res. Lab., Research Triangle Park, NC, 27709, USA  
SO Journal of Medicinal Chemistry (1991), 34(4), 1383-94  
CODEN: JMCMAR; ISSN: 0022-2623  
DT Journal  
LA English  
OS CASREACT 114:185370  
GI




AB 2,4-Diamino-6-benzylbenzimidazole I (X = N) and the corresponding indole I (X = CH), as well as more complex tri- and tetracyclic derivs. II [R = R<sub>1</sub> = H; RR<sub>1</sub> = S(CH<sub>2</sub>)<sub>2</sub>S (III)] were prepared as inhibitors of the enzyme dihydrofolate reductase (DHFR). These were designed on the basis of mol. modeling to the known x-ray structure of Escherichia coli DHFR, in an effort to determine whether one could drastically alter the diamino configuration by placing one amino substituent in a 5-membered nitrogen-containing ring and the second in the ortho position of a fused ring and still inhibit DHFR significantly. Although the electronics and bond angles are quite different from that of a 2,4-diaminopyrimidine, the pK<sub>a</sub> values are in an appropriate range, and hydrogen-bond distances appear to be quite reasonable. The most active compound, I (X = CH), was very unstable and active only in the 10<sup>-4</sup> M range. Dihydroindenoimidazole derivs. such as III showed quite a good fit to the enzyme by modeling studies, but had low activity. Since the most active compound made was 2 orders of magnitude weaker as an inhibitor of bacterial DHFR than the unsubstituted 5-benzyl-2,4-diaminopyrimidine, such a ring system was unlikely to produce the high inhibitory potency of trimethoprim, even with greatly improved hydrophobic contacts. Thus the 2,4-diaminopyrimidine system remains unparalleled to date for the competitive inhibition of this enzyme.


IT 133100-33-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and attempted catalytic hydrogenation of)  
RN 133100-33-1 CAPLUS  
CN Spiro[1,3-dioxolane-2,5'-(1'H)-indeno[5,6-d]imidazol]-2'-amine,  
6',7'-dihydro-8'-nitro- (9CI) (CA INDEX NAME)



IT 133100-32-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and catalytic hydrogenation of)  
 RN 133100-32-0 CAPLUS  
 CN Spiro[1,3-dithiolane-2,5'-(1'H)-indeno[5,6-d]imidazol]-2'-amine,  
 6',7'-dihydro-8'-nitro- (9CI) (CA INDEX NAME)



IT 133100-09-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and dihydrofolate reductase inhibitory activity of)  
 RN 133100-09-1 CAPLUS  
 CN Spiro[1,3-dithiolane-2,5'-(1'H)-indeno[5,6-d]imidazole]-2',8'-diamine,  
 6',7'-dihydro- (9CI) (CA INDEX NAME)



L8 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1961:76309 CAPLUS  
 DN 55:76309  
 OREF 55:14517c-i,14518a-i,14519a-i,14520a-f  
 TI Steroidal [3,2-c]pyrazoles. II. Androstanes, 19-norandrostanes, and their  
 unsaturated analogs  
 AU Clinton, R. O.; Manson, A. J.; Stonner, F. W.; Neumann, H. C.;  
 Christiansen, R. G.; Clarke, R. L.; Ackerman, J. H.; Page, D. F.; Dean, J.  
 W.; Dickinson, W. B.; Carabateas, Clarissa  
 CS Sterling-Winthrop Inst., Rensselaer, NY  
 SO Journal of the American Chemical Society (1961), 83, 1478-91  
 CODEN: JACSAT; ISSN: 0002-7863  
 DT Journal  
 LA Unavailable  
 OS CASREACT 55:76309  
 AB cf. CA 53, 16211b. Several types of steroidal [3,2-c]pyrazoles (I) were

prepared from 3-oxoandrostanes, 3-oxoandrost-4-enes, 3-oxoandrosta-4,6-dienes, 3-oxo-19-norandrostanes, and 3-oxo-19-norandrost-4-enes by formylation at the 2-position and reaction of the resulting 2-hydroxymethylene-3-oxo steroid (II) with N<sub>2</sub>H<sub>4</sub> or substituted hydrazine. The I frequently possessed enhanced or unusual endocrinol. activities. These included greatly increased anabolic-androgenic ratios, or the unexpected development of estrogenic activity. The appropriate 3-oxo steroid (III) treated with NaH and HCO<sub>2</sub>Et in C<sub>6</sub>H<sub>6</sub> by the method of Weisenborn, et al. (CA 49, 12482f), yielded the corresponding II; method A. NaH in C<sub>6</sub>H<sub>6</sub> treated with stirring with 5-25 mol-% absolute MeOH and after 0.5 h. with the appropriate III gave the corresponding II; method B. The appropriate III formylated by the method of Johnson and Posvic (CA 41, 6537c) with dry NaOMe in C<sub>6</sub>H<sub>6</sub> gave the corresponding II; method C. III (15 mmol) in 100 cc. dry C<sub>5</sub>H<sub>5</sub>N under N treated successively with 8.0 cc. HCO<sub>2</sub>Et and 0.66 g. Na in 6 cc. absolute MeOH, kept at room temperature overnight,

poured into 75 cc. AcOH in 700 cc. H<sub>2</sub>O, and filtered, the residue extracted with C<sub>6</sub>H<sub>6</sub> or CH<sub>2</sub>Cl<sub>2</sub>, the extract washed and extracted with 2% aqueous KOH, and the

basic extract acidified with 10 cc. AcOH yielded the corresponding II, method D. A similar procedure using an equivalent amount of dry NaOEt instead of NaOMe-MeOH gave also II; method E. By these methods were prepared the 2-hydroxymethylene derivs. of the following III (III, method, reaction time in hrs., and % yield of II given): 17 $\alpha$ -ethynylandrostan-17 $\beta$ -ol-3-one (IV), A or C, 48, 35-6 (D or E, 2 days, 81-3%, m. 170.8-7.5°); 17 $\alpha$ -Et analog of IV, C, 24, 100; 17 $\alpha$ -MeC.tplbond.C analog of IV, C, 72, 85; 17 $\alpha$ -Pr analog of IV, A, 168, 98 (B, 72 h., 98%, m. about 80°); 4,4,17 $\alpha$ -trimethyl analog of IV, D, 24, 77 (m. 150-4°); 6 $\alpha$ ,17 $\alpha$ -di-Me analog of IV, C, 24, 100 [m. 190.8-9.8° (Me<sub>2</sub>CO), [ $\alpha$ ]D 54.3° (all rotations were measured in CHCl<sub>3</sub> at 25° and 1% concentration)]; 19-norandrostan-17 $\beta$ -ol-3-one (V), D, 4, 100 (resin); 17 $\alpha$ -Me derivative of V, C, 48, 100 [m. 206.2-10.6°, [ $\alpha$ ]D 96.1°]; 17 $\alpha$ -Et derivative of V, E, 4, 60 (hydrate m. 72-115°); 17 $\alpha$ -CH.tplbond.C derivative of androst-4-en-17 $\beta$ -ol-3-one (VI), E, 24, 50 (m. 182-8°); 17 $\alpha$ -CH<sub>2</sub>:CH derivative of VI, A or B, 72, 88-94; 17 $\alpha$ -Et derivative of VI, A, 72, 100 [isolated as the Na salt monohydrate, m. 200-30° (decomposition)]; 17 $\alpha$ -CH<sub>2</sub>:CHCH<sub>2</sub> derivative of VI.0.5H<sub>2</sub>O (m. 95.4-109.8°, [ $\alpha$ ]D 75.4°), D, 96, 83; 4,4-dimethylandrost-5-en-17 $\beta$ -ol-3-one, D, 72, 71 (m. 148-54°); 4,4-dimethyl-17 $\beta$ -methoxyandrost-5-en-3-one, E, 24, 85 [m. 138.8-9.6° (iso-PrOH), [ $\alpha$ ]D -44.1°]; 4,4,17 $\alpha$ -trimethylandrost-5-en-3-one, D, 24, 83 [m. 164.2-6.0 (iso-PrOH), [ $\alpha$ ]D -59.2°]; androst-4-ene-11 $\beta$ ,17 $\beta$ -diol-3-one, A, 96, 50 (m. 168-90°); 9 $\beta$ ,11 $\beta$ -epoxy-17 $\alpha$ -methylandrost-4-en-17 $\beta$ -ol-3-one, E, 24, 100 (m. 80-115°); androsta-4,6-dien-17 $\beta$ -ol-3-one, A, 96, 95; 17 $\alpha$ -ethylandrosta-4,6-dien-17 $\beta$ -ol-3-one, A, 72, 98 (isolated as the H<sub>2</sub>O-soluble Na derivative). Androstan-17 $\beta$ -ol-3-one (VII) gave similarly by method A during 72 h., by method C during 72 h., and by method E overnight 92, 49, and 99%, resp., yield of the corresponding II. The 17 $\alpha$ -Me derivative of VII gave by methods A, B, and C during 48 h. and by method E overnight 27, 90-5, 90-5, and 99%, resp., of the corresponding II. 17 $\alpha$ -Methylandrost-4-en-17 $\beta$ -ol-3-one gave by method A during 120 h. 90% corresponding II, m. 178.6-9.8°, [ $\alpha$ ]D 14.0°. The appropriate II (0.01 mol) in 100 cc. EtOH refluxed 2-6 h. with 0.015-0.02 mol 85-100% N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O gave the corresponding I. In this manner were prepared the following [3,2-c]pyrazoles [corrected m.p., and [ $\alpha$ ]D (CHCl<sub>3</sub>) given]: 17 $\beta$ -hydroxyandrostan(VIII) ethanolate, 127.6-8.4° (EtOH), resolidified and remelted at 217-25°, 55.1°; 17 $\alpha$ -Me derivative (IX) of VIII.EtOH, 229.8-42.0° (EtOH) [solvate, prisms, m. about 148°, resolidified and remelted at 228-34°), 35.7° [48.6° (c 1, MeOH)]; N-Ac derivative of IX.EtOH (from IX

with Ac<sub>2</sub>O-C<sub>5</sub>H<sub>5</sub>N), 111.4-15.4° (EtOH), 43.1°; N-EtCO derivative of IX, 134.4-48.0° (EtOH), 45.1°; N-(p-ClC<sub>6</sub>H<sub>4</sub>OCH<sub>2</sub>CO) derivative of IX, 164.8-7.6° (Me<sub>2</sub>CO), 35.1°; 17α-CH.tplbond.C derivative of VIII, 237.4-42.0° (EtOH), 12.4°; 17α-Et derivative of VIII.H<sub>2</sub>O, 249.0-51.6° (EtOH), 32.7°; 17α-MeC.tplbond.C derivative of VIII, 143° (decomposed to a foam), -29.6° (c 1, C<sub>5</sub>H<sub>5</sub>N) [-29.3° (c 1, HCONMe<sub>2</sub>)]; 6α,17α-di-Me derivative of VIII, 156.0-74.0° (decomposition), 44.8°; 4,4,17α-tri-Me derivative of VIII, 269.2-74.6° (MeOH), 4.7° (c 1, EtOH) [5.9° (c 1, C<sub>5</sub>H<sub>5</sub>N)]; 4,4-di-Me derivative of VIII, 176.0-9.0° (MeOH), 30.0°; 17β-hydroxy-19-norandrostando- (X), 248.0-51.5° (EtOH), -; 17α-Et derivative of X, 149.2-50.4° (EtOH), 93.0° (c 1, C<sub>5</sub>H<sub>5</sub>N); 17β-hydroxyandrost-4-eno- (XI), 272.0-6.6° (EtOH), 147.6° (c 1, C<sub>5</sub>H<sub>5</sub>N); N,O-di-EtCO derivative (XII) of XI, 148.8-51.6° (Et<sub>2</sub>O-pentane), 52.4°; 17α-CH.tplbond.C derivative of XII, 239.6-6.2° (Me<sub>2</sub>CO), 29.0°; 17α-CH<sub>2</sub>:CH derivative of XII, 247.0-59.4° (EtOH), 101.2° [93.6° (c 1, dioxane)]; 17α-Et derivative of XII, 284.0-90.6° (EtOH), 102.1°; 17α-CH<sub>2</sub>:CHCH<sub>2</sub> derivative of XII, 239.8-48.2° (aqueous EtOH), 93.7°; 4,4-dimethyl-17β-hydroxyandrost-5-eno- (XIII), 231.0-3.6° (aqueous EtOH), -20.1°; 17β-MeO analog of XIII, 236.4-9.2° (iso-PrOH), -34.2°; 17α-Me derivative of XIII, 270.4-6.0° (MeOH), -55.0° (c 1, EtOH); 11β-OH derivative (XIV) of XI.EtOH, 233.2-46.0° (EtOH), 167.5° (c 1, C<sub>5</sub>H<sub>5</sub>N); N,O-di-EtCO derivative of XIV, 107.6-12.6° (MeOH), 80.7°; 9β,11β-epoxy-17β-hydroxy-17α-methylandrost-4-eno-, 233.2-46.8° (Me<sub>2</sub>CO), -145.0°; 17β-hydroxyandrosta-4,6-dieno-, 272.8-7.0° (EtOH-EtOAc), -137.2° (c 1, EtOH); 17α-ethyl-17β-hydroxyandrosta-4,6-dieno-, 305-15° (EtOH), -55.4° (c 1, C<sub>5</sub>H<sub>5</sub>N). 2-Hydroxymethyleneandrost-17β-ol-3-one (XIVa) (5.00 g.), 3.80 g. N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>SO<sub>4</sub>, and 400 cc. EtCO<sub>2</sub>H heated 5 days at 70°, poured into H<sub>2</sub>O, and extracted with Et<sub>2</sub>O gave 1.82 g. 17β-propionyloxyandrostano[3,2-c]pyrazole (XV), m. 181.2-95.2° (Et<sub>2</sub>O), [α]<sub>D</sub> 40.2°. VIII.EtOH (1.80 g.), 1.43 g. p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H, 10 cc. EtCO<sub>2</sub>H, and 25 cc. (EtCO)<sub>2</sub>O kept 24 h. at room temperature and poured into 400 cc. H<sub>2</sub>O gave 2.25 g. N-EtCO derivative of XV, needles, m. 180.0-1.8° (hexane-Et<sub>2</sub>O), [α]<sub>D</sub> 47.2°. VIII (5.00 g.) in 80 cc. C<sub>5</sub>H<sub>5</sub>N kept 20 h. at room temperature with 15.0 g. 3-cyclohexylpropionic anhydride, heated 0.5 h. on the steam bath, and worked up gave 1.12 g. N-cyclohexylpropionyl derivative (XVI) of 17β-cyclohexylpropionyloxyandrostano[3,2-c]pyrazole (XVII), needles, m. 117.8-20.8° (Et<sub>2</sub>O-MeOH), [α]<sub>D</sub> 41.4°. XVI (3.4 g.) and 40 cc. 80% AcOH refluxed 2 h. gave 1.53 g. XVII, needles, m. 236.4-8.6° (Me<sub>2</sub>CO-MeOH), [α]<sub>D</sub> 41.9°. IX (7.00 g.) in 100 cc. Ac<sub>2</sub>O refluxed 1.5 h. yielded 7.68 g. N-Ac derivative (XVIII) of 17β-acetoxy-17α-methylandrostano[3,2-c]pyrazole (XIX), needles, m. 144.4-5.8°, [α]<sub>D</sub> 55.0°. XVIII (5.73 g.) in 60 cc. 80% AcOH refluxed 1.5 h. gave 2.17 g. XIX, needles m. 224.8-6.8° (MeOH), [α]<sub>D</sub> 44.3°. MeNHNH<sub>2</sub>.H<sub>2</sub>SO<sub>4</sub> (1.52 g.) and 1.97 g. NaOAc in 80 cc. H<sub>2</sub>O added to 3.00 g. XIVa in 400 cc. EtOH and refluxed 0.5 h. yielded 2.20 g. 17β-hydroxy-17α-methylandrostano[3,2-c]-1'-methylpyrazole (XX), m. 249.6-59.0° (MeOH), [α]<sub>D</sub> 39.0° (c 1, EtOH). XIVa (8.5 g.) and 2.3 g. 2-methylsemicarbazide in the min. amount boiling BuOH refluxed 18 h. gave 4.8 g. N-methylsemicarbazone, powder, m. 140° (decomposition); a 2.7 g. portion heated 6 h. at 205° under N gave 0.78 g. 2'-Me isomer (XXI) of XX, m. 186.6-98.0° (Me<sub>2</sub>CO), [α]<sub>D</sub> 38.3° (c 1, EtOH). XX (1.85 g.), 10 cc. MeOH, and 10 cc. MeI kept 60 h. at room temperature in a sealed tube, heated 1 h. at 100°, and evaporated gave a mixture of white prisms and yellow spherulites; the mixture triturated with a few cc. CH<sub>2</sub>Cl<sub>2</sub> left 1.43 g. 17β-hydroxy-17α-methylandrostano[3,2-c]-1',2'-dimethylpyrazolium iodide, m. 282.4-91.2° (decomposition) (MeOH-MeCN), [α]<sub>D</sub> 35.8° (c 1, MeOH). XIVa (3.33 g.), 1.10 g. PhNHNH<sub>2</sub>, and

100 cc. MeOH refluxed 1.5 h. gave 3.29 g. 2'-Ph analog of XXI. MeOH, needles, decompose 99.4° to a foam,  $[\alpha]_D$  55.0°.  
17 $\alpha$ -Ethylandrostane-3 $\beta$ ,17 $\beta$ -diol (5.1 g.) in 125 cc. C<sub>5</sub>H<sub>5</sub>N treated with 5.0 g. CrO<sub>3</sub> gave 2.05 g. 17 $\alpha$ -ethylandrostan-17 $\beta$ -ol-3-one, m. 287.4-9.4° (EtOH),  $[\alpha]_D$  -25.4° (c 1, C<sub>5</sub>H<sub>5</sub>N). 17 $\alpha$ -Vinylandrostane-3 $\beta$ ,17 $\beta$ -diol (3.18 g.) in 20 cc. dry C<sub>5</sub>H<sub>5</sub>N treated with 1.33 g. CrO<sub>3</sub> gave 2.50 g. 17 $\alpha$ -vinylandrostan-17 $\beta$ -ol-3-one (XXII), needles, m. 183.0-3.6° (EtOAc),  $[\alpha]_D$  8.8°. XXII formylated by method C during 3 days gave 36-7% 2-HOCH<sub>2</sub> derivative (XXIII) of XXII, m. 132-7°. Method C at 45-50° during 2 days and method D during 2-48 h. yielded 47-53 and 4-15%, resp., of XXIII. Crude XXIII condensed with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O yielded the 17 $\alpha$ -CH<sub>2</sub>:CH derivative of VIII, prisms, m. above 300° (MeOH),  $[\alpha]_D$  24.5°.  
Androstan-3 $\beta$ -ol-17-one (46.3 g.) in 400 cc. dry Et<sub>2</sub>O kept 3 days at room temperature with 0.9 g. p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H.H<sub>2</sub>O yielded 38.0 g. epimeric mixture

of

3-tetrahydropyranyl ethers (XXIV), m. 160-95°. MeC.tplbond.CH (30 g.) added with stirring during 1 h. under dry ice-cooled reflux to 0.3 EtMgBr in 100 cc. Et<sub>2</sub>O and 250 cc. THF (THF), the mixture treated slowly dropwise with 33.5 g. XXIV in 250 cc. dry THF, refluxed overnight, treated with 50 cc. saturated aqueous NH<sub>4</sub>Cl, and worked up, and the crude product dissolved in 300 cc. EtOH, treated with 5 cc. 85% H<sub>3</sub>PO<sub>4</sub>, kept 2 days at room temperature, and diluted with H<sub>2</sub>O gave 22.6 g. 17 $\alpha$ -propynylandrostane-3 $\beta$ ,17 $\beta$ -diol, m. above 150°, which oxidized with 18.0 g. CrO<sub>3</sub> and 300 cc. C<sub>5</sub>H<sub>5</sub>N gave 66% 17 $\alpha$ -propynylandrostan-17 $\beta$ -ol-3-one, prisms, m. 192.8-7.0° (MeOH),  $[\alpha]_D$  -18.7°, -28.2° (c 1, C<sub>5</sub>H<sub>5</sub>N). 17 $\alpha$ -Allylandrost-5-ene-3 $\beta$ ,17 $\beta$ -diol in EtOH hydrogenated over 22% Pd-SrCO<sub>3</sub> gave 17 $\alpha$ -propylandrostane-3 $\beta$ ,17 $\beta$ -diol, needles, m. 188.6-91.0° (EtOAc),  $[\alpha]_D$  -5.3°, which oxidized with CrO<sub>3</sub>-C<sub>5</sub>H<sub>5</sub>N gave 17 $\alpha$ -propylandrostan-17 $\beta$ -ol-3-one, prisms, m. 131.8-2.4° (EtOAc),  $[\alpha]_D$  15.5°. 6 $\alpha$ ,17 $\alpha$ -Dimethylandrost-4-en-17 $\beta$ -ol-3-one (10 g.) in 150 cc. dry Et<sub>2</sub>O and 150 cc. dry THF stirred 50 min. with 2.5 g. Li and worked up, and the crude product (9.87 g.) oxidized in 100 cc. C<sub>5</sub>H<sub>5</sub>N with 10.0 g. CrO<sub>3</sub> yielded 6 $\alpha$ , 17 $\alpha$ -dimethylandrostan-17 $\beta$ -ol-3-one, prisms, m. 181.6-4.6° (EtOAc),  $[\alpha]_D$  10.3°. 2-Hydroxymethylene-7 $\alpha$ -methyl-19-norandrostan-17 $\beta$ -ol-3-one condensed in the usual manner with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O gave 17 $\beta$ -hydroxy-17 $\alpha$ -methyl-19-norandrostan-3,2-c-pyrazole-EtOH, m. 146-56° (EtOH); it gave also an Me<sub>2</sub>CO solvate, m. 148° (decomposition), and an EtOAc solvate, m. 125-6° (decomposition), which heated 48 h. in vacuo at 110° gave the solvent-free material, m. 140.4-52.4°,  $[\alpha]_D$  90.0°.  
XII (2.33 g.) in 50 cc. 80% AcOH refluxed 1.5 h. gave 17 $\beta$ -propionyloxyandrost-4-eno[3,2-c]pyrazole, m. 166.6-72.0° (Me<sub>2</sub>CO-hexane),  $[\alpha]_D$  99.5°. XI (5.0 g.) in 200 cc. MeOH treated with 0.016 mol HCl in 15 cc. Et<sub>2</sub>O and then 40 cc. H<sub>2</sub>O, followed by 1.3 g. KOCN in 10 cc. H<sub>2</sub>O, and filtered yielded 4.2 g. N-carbamoyl derivative (XXV), m. 227-8°,  $[\alpha]_D$  83.4° (c 1, C<sub>5</sub>H<sub>5</sub>N), of XI. XXV (8.0 g.) in 500 cc. AcOH treated dropwise at about 14° during 10 min. with 3.2 g. CrO<sub>3</sub> in 8 cc. H<sub>2</sub>O and 24 cc. glacial AcOH, stirred 2 h. at 14°, and 3 h. at room temperature, and worked up gave 4.8 g. N-carbamoyl derivative (XXVI) of 17-oxoandrost-4-eno[3,2-c]pyrazole (XXVII), needles, m. 273-4° (CHCl<sub>3</sub>),  $[\alpha]_D$  136.3°, 142.2° (c 0.25, C<sub>5</sub>H<sub>5</sub>N). XXVI (4.57 g.), 1800 cc. EtOH, and 10 cc. concentrated HCl refluxed 6 h., concentrated to 900 cc., diluted with 600 cc. H<sub>2</sub>O and 20 cc.

concentrated

NH<sub>4</sub>OH, concentrated, and filtered gave 3.95 g. of product, prisms, m. 258.6-63.8°,  $[\alpha]_D$  209.4°, 211.8° (c 1, C<sub>5</sub>H<sub>5</sub>N), 199.1° (c 1, EtOH). 2-Hydroxymethylene-17 $\alpha$ -methylandrost-4-en-17 $\beta$ -ol-3-one (XXVIII) with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O gave 17 $\beta$ -hydroxy-17 $\alpha$ -methylandrost-4-eno[3,2-c]pyrazole (XXIX), plates, m. 250.0-8.0° (EtOH),  $[\alpha]_D$  103.5° (c 1, MeOH),

133.2° (c 1, C<sub>5</sub>H<sub>5</sub>N). XXIX with Ac<sub>2</sub>O-C<sub>5</sub>H<sub>5</sub>N during 48 h. at room temperature yielded the N-Ac derivative of XXIX, m. 92.0-100.2° (EtOH), [α]<sub>D</sub> 67.1°, 87° (c 1, C<sub>5</sub>H<sub>5</sub>N). XXVIII with MeNHNH<sub>2</sub> in aqueous EtOH gave 44% 1-Me derivative (XXX) of XXIX, prisms, m. 175.2-93.2° (MeCN), [α]<sub>D</sub> 103.6°, 132.9° (c 1, C<sub>5</sub>H<sub>5</sub>N). XXX (5.25 g.), 10 cc. MeOH, and 15 cc. MeI heated 2.5 h. at 100° in a sealed tube gave 2.05 g. 17β-hydroxy-17α-methylandrosta-4-eno[3,2-c]1',2'-dimethylpyrazolium iodide, pale yellow, m. 257.8-61.6° (decomposition) (EtOH), [α]<sub>D</sub> 13.3° (c 1, MeOH). 17α-Propargylandrost-4-en-17β-ol-3-one, m. 135.8-43.2°, [α]<sub>D</sub> 65.2°, formylated by method B during 6 days, and the crude 2-hydroxymethylene derivative (84%) condensed with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O gave 17α-HC.tplbond.CCH<sub>2</sub> analog of XXIX, prisms, m. 130.4-40.6° (aqueous EtOH), [α]<sub>D</sub> 75.4°. 17α-Propylandrost-5-ene-3β,17β-diol, m. 188.0-92.8°, [α]<sub>D</sub> -59.2°, subjected to an Oppenauer oxidation gave 17α-propylandrost-4-en-17β-ol-3-one (XXXI), plates, m. 114.6-16.0° (C<sub>6</sub>H<sub>6</sub>-hexane), [α]<sub>D</sub> 75.4°. XXXI formylated by method A during 3 days, and the resulting crystalline 2-hydroxymethylene derivative condensed in the usual manner with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O gave a small amount of 17-methyl-17-propylandrosta-4,12(13)-dieno[3,2-c]pyrazole, needles, m. 203.0-12.0°, and mainly 17α-Pr analog of XXIX, plates, m. 223.0-32.4° (aqueous EtOH), [α]<sub>D</sub> 89.5°. 6α,17α-Dimethylandrosta-4-en-17β-ol-3-one formylated by method A during 5 days, and the resulting 2-HOCH<sub>2</sub> derivative (85%), m. 145-65°, condensed with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O yielded 6α,17α-dimethyl-17β-hydroxyandrosta-4-eno[3,2-c]pyrazole, needles, m. 170.0-8.6° (decomposition) (EtOAc). 6α-Methyl-17α-propynylandrost-4-en-17β-ol-3-one formylated by method D during 2 days, and the crude product (100%), m. 108-30°, condensed with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O yielded 17β-hydroxy-6α-methyl-17α-propynylandrost-4-eno[3,2-c]pyrazole, m. 166.2-70.6° (MeOH), [α]<sub>D</sub> 7.6°. The mother liquors from the preparation of 4,4-dimethylandrosta-5-en-17β-ol-3-one chromatographed on Al<sub>2</sub>O<sub>3</sub> gave 4,4-dimethyl-17β-methoxyandrosta-5-en-3-one, needles, m. 134.4-8.2° (MeOH), [α]<sub>D</sub> -15.0°. 9α-Fluoro-17α-methylandrosta-4-ene-11β,17β-diol-3-one formylated by method E during 6 days, and the resulting glassy, resinous 2-HOCH<sub>2</sub> derivative condensed with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O gave 11β,17β-dihydroxy-9α-fluoro-17α-methylandrosta-4-eno[3,2-c]pyrazole, m. 281° (decomposition) (Me<sub>2</sub>CO-EtOAc), [α]<sub>D</sub> 101.3° (c 1, EtOH). 9α-Fluoro-17α-methylandrosta-4-en-17β-ol-3,11-dione formylated with HCO<sub>2</sub>Et by method B during 5 days, and the resulting crude 2-HOCH<sub>2</sub> derivative condensed with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O yielded 9α-fluoro-17β-hydroxy-11-oxo-17α-methylandrosta-4-eno[3,2-c]pyrazole, m. 292-300° (decomposition), [α]<sub>D</sub> 119.6° (c 0.15, EtOH). 2-Hydroxymethylene-17α-methyl-19-norandrosta-4-en-17β-ol-3-one condensed with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O gave 17β-hydroxy-17α-methyl-19-norandrosta-4-eno[3,2-c]pyrazole-0.5EtOH (XXXII.0.5EtOH), needles m. 111.0-26.1° (decomposition) (EtOH), [α]<sub>D</sub> 0.2°, which with excess (EtCO)<sub>2</sub>O during 48 h. at room temperature gave the N-EtCO derivative, m. 131.8-4.2°, [α]<sub>D</sub> -6.4°. 17α-Ethyl-19-norandrosta-4-en-17β-ol-3-one formylated by method B during 4 days, and the resulting crude 2-HOCH<sub>2</sub> derivative (85%), m. 87-100°, condensed with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O gave 17α-Et analog of XXXII, m. from 147° with gradual decomposition (MeCOEt), [α]<sub>D</sub> 59.1° (c 1, C<sub>5</sub>H<sub>5</sub>N). 17α-Methylandrosta-4,6-dien-17β-ol-3-one gave by method C during 3 days 100% crude 2-HOCH<sub>2</sub> derivative, m. from 87° with gradual decomposition, which condensed with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O gave 52% 17β-hydroxy-17α-methylandrosta-4,6-dieno[3,2-c]pyrazole (XXXIII), yellow plates, m. 279.2-84.0° (EtOAc), [α]<sub>D</sub> -126.1° (c 1, C<sub>5</sub>H<sub>5</sub>N); N-Ac derivative of XXXIII, m. 151.8-4.8° (Et<sub>2</sub>O-pentane), [α]<sub>D</sub> -244°, -192° (c 1, C<sub>5</sub>H<sub>5</sub>N). 17α-Ethyltestosterone brominated with N-bromosuccinimide and the resulting 6-Br derivative dehydrobrominated with collidine gave 17α-ethylandrosta-4,6-dien-17β-ol-3-one, yellow needles, m.

Absolute stereochemistry.

